Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Respiratory Research

Fig. 3

From: ZDHXB-101 (3′,5-Diallyl-2, 4′-dihydroxy-[1,1′-biphen-yl]-3,5′-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways

Fig. 3

Effects of ZDHXB-101 on airway hyperresponsiveness. The lung function of mice in response to aerosolized methacholine (3.125–50 mg/mL) was measured 24 h after the last challenge with treatment of ZDHXB-101 at doses of 3 mg/kg and 10 mg/kg. Airway resistance was shown as Penh values. The results were expressed as percentage change in Penh above baseline. The data represent means ± S.D. (n = 10), *p < 0.05 and ***p < 0.001 vs. the control group. #p < 0.05 and ##p < 0.01 vs. the model group

Back to article page